Skip to Content
Top of Page: How to talk to a doctor about advanced ovarian cancer >>

Bexarotene Pregnancy and Breastfeeding Warnings

Bexarotene is also known as: Targretin

Bexarotene Pregnancy Warnings

Because women of child bearing potential may be unaware that they are pregnant, pregnancy testing is recommended within one week prior to initiation of therapy, monthly while on therapy, and for at least one month after discontinuation of therapy. Bexarotene therapy may be initiated on the second or third day of a normal menstrual cycle if a negative pregnancy test result has been obtained within the past week. Effective contraception is recommended for one month before the initiation of therapy, during therapy, and for at least one month following the discontinuation of therapy. The manufacturer recommends that two forms of reliable contraception be used and that one of these be non-hormonal. It is also recommended that male patients with sexual partners who are pregnant, possibly pregnant, or who could become pregnant, use condoms during sexual intercourse while on bexarotene therapy and for at least one month after the discontinuation of therapy.

Bexarotene has been assigned to pregnancy category X by the FDA. Animal studies have revealed evidence of malformations. There are no controlled data in human pregnancy. Bexarotene is considered contraindicated during pregnancy.

See references

Bexarotene Breastfeeding Warnings

There are no data on the excretion of bexarotene into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.

References for breastfeeding information

  1. "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.